| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.09. | Truist Securities initiates Rapport Therapeutics stock with Buy rating | 5 | Investing.com | ||
| 11.09. | Rapport Therapeutics, Inc.: Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit | 1 | GlobeNewswire (USA) | ||
| 10.09. | Rapport Therapeutics prices $250M stock at $26 per share | 2 | Seeking Alpha | ||
| RAPPORT THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 10.09. | Rapport Therapeutics prices $250 million public offering at $26 per share | 2 | Investing.com | ||
| 10.09. | Rapport Therapeutics, Inc.: Rapport Announces Pricing of Public Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
| 08.09. | Rapport Therapeutics launches $250 million public stock offering | 15 | Investing.com | ||
| 08.09. | Rapport Therapeutics, Inc.: Rapport Announces Proposed Public Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
| 08.09. | Rapport Therapeutics: Stifel hebt Kursziel nach Studienerfolg deutlich auf 56 $ an | 2 | Investing.com Deutsch | ||
| 08.09. | Stifel raises Rapport Therapeutics stock price target to $56 on positive trial data | 2 | Investing.com | ||
| 08.09. | Rapport Therapeutics Stock Rises To 117% After Positive Phase 2a Trial Results | 3 | RTTNews | ||
| 08.09. | TD Cowen bestätigt Kaufempfehlung für Rapport Therapeutics nach starken Studiendaten | 3 | Investing.com Deutsch | ||
| 08.09. | Rapport Therapeutics stock rating reiterated as Buy by TD Cowen | 16 | Investing.com | ||
| 08.09. | Rapport Therapeutics stock soars after positive Phase 2a seizure drug results | 13 | Investing.com | ||
| 08.09. | Rapport Therapeutics: Aktie springt nach positiven Phase-2a-Studienergebnissen um 160 % | 2 | Investing.com Deutsch | ||
| 08.09. | Rapport Therapeutics: Phase 2a Trial Of RAP-219 Meets Primary Endpoint | 1 | RTTNews | ||
| 08.09. | Rapport Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 08.09. | Rapport Therapeutics, Inc.: Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures | 294 | GlobeNewswire (Europe) | Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well toleratedPatients achieved 77.8% reduction in clinical seizures (p=0.01), with 24% achieving... ► Artikel lesen | |
| 05.09. | Rapport Therapeutics soars 23% on release of phase 2 data for seizure asset | 2 | Seeking Alpha | ||
| 05.09. | Rapport Therapeutics kündigt Vorstellung von Phase-2a-Studienergebnissen für Epilepsie-Medikament an | 9 | Investing.com Deutsch | ||
| 05.09. | Rapport Therapeutics to report phase 2a trial results for epilepsy drug | 3 | Investing.com |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 6,972 | +1,54 % | Aktien Frankfurt: Solide Zahlen aus den USA schieben Kurse an | FRANKFURT (dpa-AFX) - Überwiegend robuste Quartalsbilanzen und Prognosen von US-Unternehmen haben dem deutschen Aktienmarkt am Dienstag etwas Anschub verliehen. Der Leitindex Dax, der sich bis zum... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | - | - | Palatin Technologies, Inc.: Palatin Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration with Boehringer Ingelheim | Collaboration focused on developing potential first-in-class melanocortin receptor targeted treatment for patients with diabetic retinopathy, including diabetic... ► Artikel lesen | |
| VIKING THERAPEUTICS | 29,570 | -0,07 % | Viking Therapeutics-Aktie: Die spannendste Adipositas-Wette? | Nach unserem letzten Kauftipp Ende vergangenen Monats hat die Aktie von Viking Therapeutics wieder Fahrt aufgenommen und konnte über 20% zulegen. Vor den kommenden Quartalszahlen kocht die Spannung... ► Artikel lesen | |
| ABIVAX | 78,50 | +0,64 % | EQS-News: ABIVAX: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies | EQS-News: ABIVAX
/ Key word(s): Conference/Study results
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without... ► Artikel lesen | |
| GERON | 1,059 | -0,33 % | Geron Corporation Announces Executive Leadership Transitions and Appointments | FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 4,000 | +6,67 % | Cellectar Biosciences, Inc. - S-1, General form for registration of securities | ||
| GALAPAGOS NV | 27,560 | +0,29 % | Galapagos NV: Galapagos to Present In Vitro Data at ACR Convergence 2025 Suggesting Differentiation of GLPG3667 from Other TYK2 Inhibitors | Mechelen, Belgium; October 23, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present new in vitro pharmacological data from its selective TYK2 inhibitor, GLPG3667... ► Artikel lesen | |
| VIDAC PHARMA | 0,520 | -0,38 % | PTA-Adhoc: Vidac Pharma Holding PLC: Geplanter Antrag auf Einbeziehung in den Freiverkehr der Börse Düsseldorf (Teilbereich Primärmarkt) | DJ PTA-Adhoc: Vidac Pharma Holding PLC: Geplanter Antrag auf Einbeziehung in den Freiverkehr der Börse Düsseldorf (Teilbereich Primärmarkt)
Veröffentlichung von Insiderinformationen gemäß Artikel... ► Artikel lesen | |
| CYTOKINETICS | 50,000 | +0,40 % | Cytokinetics, Incorporated: Cytokinetics to Announce Third Quarter Results on November 5, 2025 | ||
| PALISADE BIO | 1,725 | -2,54 % | Palisade Bio, Inc.: Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn's Disease (FSCD) | First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapies Topline safety, PK, and PD data anticipated in Q1 2026 Advances ongoing... ► Artikel lesen | |
| FIBROGEN | 8,950 | -5,29 % | XFRA 1FG0: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| SPERO THERAPEUTICS | 1,892 | -0,84 % | GSK unveils positive pivotal data for Spero's once-rejected oral antibiotic | ||
| MINERVA NEUROSCIENCES | 4,260 | +4,93 % | Minerva Neurosciences: NBC-Tipp wird zum Tenbagger! | Anfang des Monats berichteten wir über hohe Preissprünge bei der Aktie von Minerva Neurosciences. Jetzt ist klar: Das anfängliche Kursspektakel bei der Biotech-Empfehlung des No Brainer Club war lediglich... ► Artikel lesen | |
| ROIVANT SCIENCES | 15,505 | -0,93 % | Roivant Sciences: Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM) | Once-daily oral brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all nine key secondary endpoints, including... ► Artikel lesen | |
| LIQUIDIA | 18,850 | -1,98 % | Liquidia Technologies, Inc.: Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update | YUTREPIA surpasses 900 unique patient prescriptions and 550 patient starts within 11 weeks after approval to treat PAH and PH-ILDPositive interim data from ASCENT trial reinforces YUTREPIA's tolerability... ► Artikel lesen |